Abstract
The need of using chemically modified siRNA agents for gene silencing continuously increasing as appropriate chemical modification improves their specificity, nuclease stability, potency, and in vivo cellular delivery. The future success of RNAi technology also depends on identifying drug carriers that are non-toxic and tissue-specific in directing the RNAi agents to the desired locations in a cost effective fashion. This review will cover recently reported chemically modified siRNA agents for improving specificity and potency of mRNA knockdown, their nuclease stability, cellular uptake and improved biodistribution. In addition to the chemical modifications and their biological impact, this review also focuses on the in vivo RNAi delivery techniques.
Keywords: Chemical modification, siRNA, RNA interference, RNAi agents, Gene-silencing, miRNA, In vivo RNAi
Current Bioactive Compounds
Title: Chemical Modifications of Synthetic RNAi Agents and in vivo Delivery Techniques
Volume: 4 Issue: 1
Author(s): Anilkumar R. Kore and Lance P. Ford
Affiliation:
Keywords: Chemical modification, siRNA, RNA interference, RNAi agents, Gene-silencing, miRNA, In vivo RNAi
Abstract: The need of using chemically modified siRNA agents for gene silencing continuously increasing as appropriate chemical modification improves their specificity, nuclease stability, potency, and in vivo cellular delivery. The future success of RNAi technology also depends on identifying drug carriers that are non-toxic and tissue-specific in directing the RNAi agents to the desired locations in a cost effective fashion. This review will cover recently reported chemically modified siRNA agents for improving specificity and potency of mRNA knockdown, their nuclease stability, cellular uptake and improved biodistribution. In addition to the chemical modifications and their biological impact, this review also focuses on the in vivo RNAi delivery techniques.
Export Options
About this article
Cite this article as:
Kore R. Anilkumar and Ford P. Lance, Chemical Modifications of Synthetic RNAi Agents and in vivo Delivery Techniques, Current Bioactive Compounds 2008; 4 (1) . https://dx.doi.org/10.2174/157340708784533375
DOI https://dx.doi.org/10.2174/157340708784533375 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Bioconjugation of Polymers: A Novel Platform for Targeted Drug Delivery
Current Pharmaceutical Design A179L, a New Viral Bcl2 Homolog Targeting Beclin 1 Autophagy Related Protein
Current Molecular Medicine Defective HIF Signaling Pathway and Brain Response to Hypoxia in Neurodegenerative Diseases: Not an “Iffy” Question!
Current Pharmaceutical Design Neuroimmune Crosstalk in CNS Disorders: The Histamine Connection
Current Pharmaceutical Design Phosphoinositide 3-Kinases as Targets for Therapeutic Intervention
Current Pharmaceutical Design Glycogen Synthase Kinase-3 - An Overview of An Over-Achieving Protein Kinase
Current Drug Targets Mechanisms of Action of Imidazoacridinone and Triazoloacridinone Derivatives in View of their Biological Activity
Current Pharmaceutical Analysis MicroRNAs and Targeted Therapies in Non-small Cell Lung Cancer: Minireview
Anti-Cancer Agents in Medicinal Chemistry Activation of p53 by Specific Agents in Potential Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Hydatid Disease: Current Status of Chemotherapy and Drug Delivery Systems
Current Drug Therapy Macromolecular and Nanotechnological Modification of Camptothecin and its Analogs to Improve the Efficacy
Current Drug Discovery Technologies Magnetic Field-Assisted Gene Delivery: Achievements and Therapeutic Potential
Current Gene Therapy RETRACTED: Novel and safer self-inactivating vectors for gene therapy of Wiskott-Aldrich Syndrome
Current Gene Therapy Molecular Modelling and QSAR in the Discovery of HIV-1 Integrase Inhibitors
Current Computer-Aided Drug Design Targeting MDM4 as a Novel Therapeutic Approach for Hematologic Malignancies
Current Cancer Drug Targets Recent Advances of Natural and Synthetic β-Carbolines as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry YB-1 Activities in Oncogenesis: Transcription and Translation
Current Cancer Therapy Reviews Minor-Groove Binding Agents: Rational Design of Carboxamide Bond Isosteres
Current Topics in Medicinal Chemistry Medicinal Plants and Cancer Chemoprevention
Current Drug Metabolism Metallic Colloid Nanotechnology, Applications in Diagnosis and Therapeutics
Current Pharmaceutical Design